COVID-19 Rapid Diagnostic Test Market
Expanding COVID-19 occurrence, product dispatches, and administrative endorsements are relied upon to drive the global COVID-19 rapid diagnostic test market development. For example, in September 2018, F. Hoffmann-La Roche Ltd, a Switzerland-based drug organization, declared the launch of Elecsys Anti-SARS-CoV-2 S antibody test, which can be utilized for identification of SARS-CoV-2 in human serum and plasma.
๐๐ฅ๐ข๐๐ค ๐๐๐ซ๐ ๐ญ๐จ ๐๐๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ (๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐๐๐๐ซ: ๐๐ฉ ๐ญ๐จ ๐๐% ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ ๐๐จ๐ซ ๐ ๐๐ข๐ฆ๐ข๐ญ๐๐ ๐๐ข๐ฆ๐) @ https://www.coherentmarketinsights.com/insight/request-sample/4568
Global COVID-19 Rapid Diagnostic Test Market-Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 infection episode in December 2019, the illness has spread to more than 100 nations across the globe and the World Health Organization has announced it a general wellbeing crisis.
The global occurrence of Covid is escalating demand for cutting-edge diagnostic test kits, as would be considered normal to support the development of the global COVID-19 rapid diagnostic test market. Also expanding product dispatches is relied upon to drive the covid 19 rapid diagnostic test market development. For example, in May 2020, Sherlock Biosciences, a Cambridge-based biotechnology organization, got the U.S. FDA endorsement for crisis use approval (EUA) for its CRISPR-based COVID-19 diagnostic test. The unit is for the subjective identification of SARS-CoV-2 nucleic corrosive in samples from the upper respiratory parcel and bronchoalveolar lavage of individuals thought with COVID-19.
๐๐๐ญ ๐ ๐ฎ๐ฅ๐ฅ ๐๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐๐ฉ๐จ๐ซ๐ญ: (๐๐ง๐๐ฅ๐ฎ๐๐ข๐ง๐ ๐ ๐ฎ๐ฅ๐ฅ ๐๐๐, ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐๐ฅ๐๐ฌ & ๐ ๐ข๐ ๐ฎ๐ซ๐๐ฌ, ๐๐ก๐๐ซ๐ญ) @ https://www.coherentmarketinsights.com/insight/request-pdf/4568
Key Takeaways of the Global COVID-19 Rapid Diagnostic Test Market:
- The global COVID-19 rapid diagnostic test market is relied upon to show a CAGR of 8.8% during the gauge time frame. Expanding development in innovation and rising product endorsements for the COVID-19 location are relied upon to move the market development over the gauge time frame.
For example, in March 2021, Roche Holding AG, a Swiss drug organization, sent off its new evolved rapid antigen nasal unit for faster determination of COVID-19 disease in something like 15 minutes of sample assortment and guarantees least contact between the medical care proficient and the suspected COVID-19 positive patient.
- Among product type, reagents and kits fragment is relied upon to show the fastest development over the gauge time frame, inferable from market players zeroing in on-pack dispatches and endorsements. For example, in September 2020, Veredus Laboratories, a Singapore-based diagnostic apparatuses producer and supplier, sent off its new product VereRT ZeroPrep COVID-19 PCR Kit.
- Based on regions, North America is assessed to hold the biggest market share in the global COVID-19 rapid diagnostic test market in 2021. This is inferable from expanding number of product dispatches and endorsements related to COVID-19 rapid diagnostic tests by administrative bodies. For example, on April 13, 2020, Becton, Dickinson and Company got the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular diagnostic test for COVID-19, which gives the extra testing ability to COVID-19.
- Key part working in the global COVID-19 rapid diagnostic include Creative Diagnostics, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Acon Laboratories, Inc., Alfa Scientific Designs, Inc., Cardinal Health, Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.
๐๐ซ๐๐ ๐ญ๐ก๐ ๐๐๐๐๐ซ ๐๐๐ง๐ญ๐ข๐จ๐ง๐๐ ๐๐๐จ๐ฏ๐ ๐๐ฅ๐จ๐๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค ๐๐ง๐ ๐ ๐จ๐ซ๐๐๐๐ฌ๐ญ ๐๐๐๐-๐๐๐๐ @ https://www.coherentmarketinsights.com/promo/buynow/4568
Competitive Landscape:
- Global COVID-19 Rapid Diagnostic Test Market, By Product Type:
- Instruments
- Reagents & Kits
- Global COVID-19 Rapid Diagnostic Test Market, By Sample Type:
- Nasopharyngeal (NP) Swabs
- Oropharyngeal (OP) Swabs
- Nasal Swabs
- Blood
- Others (others include Saliva)
- Global COVID-19 Rapid Diagnostic Test Market, By Test Type:
- Molecular Testing
- Antigen-based Testing
- Antibody Testing
- Others (others include CRISPR and Biosensors)
- Global COVID-19 Rapid Diagnostic Test Market, By End User:
- Hospitals & Clinic
- Laboratories & Diagnostics Centers
- Others
- Global COVID-19 Rapid Diagnostic Test Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- North America
Browse Press Release: https://www.coherentmarketinsights.com/press-release/covid-19-rapid-diagnostic-test-market-3810
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837